Volume | 109,342 |
|
|||||
News | - | ||||||
Day High | 6.35 | Low High |
|||||
Day Low | 5.80 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.35 | 5.80 | 6.35 | 6.27 | 6.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
927 | 109,342 | $ 6.03 | $ 659,291 | - | 2.58 - 11.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:04:58 | 1 | $ 6.15 | USD |
ESSA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
276.49M | 44.24M | - | 0 | -26.58M | -0.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ESSA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.22 | 6.4843 | 5.5795 | 6.28 | 69,945 | 0.05 | 0.80% |
1 Month | 6.13 | 7.70 | 5.5201 | 6.29 | 46,068 | 0.14 | 2.28% |
3 Months | 9.01 | 9.60 | 5.5201 | 7.45 | 58,989 | -2.74 | -30.41% |
6 Months | 5.85 | 11.67 | 4.91 | 8.36 | 109,742 | 0.42 | 7.18% |
1 Year | 3.05 | 11.67 | 2.58 | 6.18 | 109,215 | 3.22 | 105.57% |
3 Years | 32.70 | 33.84 | 1.40 | 6.09 | 483,895 | -26.43 | -80.83% |
5 Years | 2.60 | 36.00 | 1.40 | 7.63 | 335,150 | 3.67 | 141.15% |
ESSA Pharma Description
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |